have previously published in the subject area.
Epidemiology
The reported prevalence of HL is variable. Many studies that define HL as greater than 35 dB report the prevalence to be 1-2 per 1,000 live births and increasing. Of the prelingual HL, approximately 50-60% are attributable to genetic or inherited causes. The remaining are believed to be due to acquired or environmental reasons (drugs, trauma, noise, and infections), specifically TORCH syndromes (toxoplasmosis, other agents, rubella, cytomegalovirus, herpes simplex; Mason & Herrmann, 1998; Morton & Nance, 2006; Morton 1991) . Recent advancements in neonatal care, immunization, and drug monitoring have decreased the incidence of HL attributable to environmental factors (Grundfast, Siparsky, & Chuong, 2000; Smith & Hone, 2003) .
Of the inherited causes, autosomal recessive (AR) makes up 75-80% of cases followed by autosomal dominant (AD) 10-20%, sex-linked 1-5%, and mitochondrial 0-2% (Grundfast et al., 2000; Petersen 2002; Smith & Hone, 2003) . Nearly 70% of all these inherited HL cases present are non-syndromic HL, meaning no other diseases in the body are identifiable with the hearing loss. The number of non-syndromic cases is increasing as new loci and genes are discovered.
Non-syndromic HL is always attributed to a single gene defect and presents as a single trait. The most frequent mode of inheritance is AR. There is a standard nomenclature for the loci and genes responsible for single trait HL: DFNA for autosomal dominant, DFNB for autosomal recessive, DFN for X-linked and DFNM for modifiers of other genes (Morton & Nance, 2006) . Single genes have been shown to cause both syndromic and non-syndromic HL or show both dominant and recessive inheritance patterns. These genes have more than one identified locus. Mutations in different loci will result in a HL that is inherited dominant, recessive, or is associated with other clinical features (Kochhar, Hildebrand, & Smith, 2007) .
Autosomal Dominant
Waardenburg's syndrome, the most common AD syndromic HL, is categorized into 4 subtypes. Type 1, the most common, is characterized by the presence of bilateral or unilateral SNHL in 15-20% of cases. There are defects in the tissues of neural crest origin. The latter includes wide set eyes, broad nose root, and hypopigmentations in skin (white forelock) and discoloration of the eyes (heterochromia iridis). The remainder of the subtypes are summarized in Table 1A . Branchio-oto-renal (BOR) syndrome is the second most common AD syndromic HL. It has an approximately 2% prevalence among severe to profound HL population. It is characterized by association of branchial, otologic, and renal abnormalities. Hearing loss (HL) is found in 70-100% of cases and considered a major feature of this syndrome. The HL can be conductive, sensorineural, or mixed. It can manifest between early childhood and young adulthood, and is variable even within members of a family (Heimler, Lieber, Opitz, & Reynolds, 1986; Hone & Smith, 2001; Ruf et al., 2004) . Some of the other major but less common forms of non-syndromic AD HL are described in Table 1A .
Mutations in WFS1, KCNQ4, COCH, and GJB2 genes are more frequent among AD genes causing a non-syndromic HL (Hilgert et al., 2009) . WFS1 mutation can result in a syndromic HL (Wolfram syndrome) or non-syndromic HL (DFNA6/14/38; Finsterer & Fellinger, 2005) . KCNQ4 encodes a potassium channel subunit in the outer hair cells of cochlea (Topsakal et al., 2005; Van Camp et al., 2002) . These patients present with postlingual, moderate to severe, highfrequency SNHL. Vertigo could be associated with KCNQ4 mutations, and tinnitus could occur with GJB3 mutations (Finsterer & Fellinger, 2005; Hilgert et al., 2009) .
Mutations in TECTA gene is not as frequent as WFS1 or KCNQ4 (8 mapped mutations) but gives rise to a significant HL (Pfister et al., 2004) . The gene encodes alpha-Tectorin, a major component of the tectorial membrane and results in progressive, moderate to severe, high-frequency SNHL which could present pre-or postlingual (Finsterer & Fellinger, 2005) . Some of the other major forms of non-syndromic AD HL are described in Table 1B . 
Autosomal Recessive
Pendred syndrome, the most frequent syndromic HL, accounts for approximately 4-8% of individuals with severe to profound HL. Clinical features include SNHL, goiter (euthyroid or hypothyroid), and structural defects of the temporal bone and inner ear. Sensorineural (SNHL) is accompanied with various abnormalities of inner ear such as Mondini dysplasia (incomplete cochlea with less than normal 2.5 turns), dilated vestibular aqueduct, and vestibular malfunction (Everett et al., 1997; Phelps et al., 1998; Tekin, Arnos, & Pandya, 2001 ). The underlying genetic etiology is a mutation in Pendred Syndrome (PDS) gene that encodes pendrin (an iodide-chloride pump; Nance, 2003) .
Usher syndrome is the association of SNHL with retinitis pigmentosa (RP). It is one of the most common forms of AR syndromic HL with a prevalence of 3-6% in severe to profound HL population. In addition, it accounts for 50% of the deaf-blind individuals in United States. It is divided into three different types (Kimberling et al., 1989; Rosenberg, Haim, Hauch, & Parving, 1997; Tekin et al., 2001) . Some of the other major forms of syndromic AR HL are described in Table 2A . Although AR non-syndromic HL is more likely to be seen in societies with high rate of consanguineous marriages, the most frequent mutations causing non-syndromic HL occur in genes with AR inheritance patterns (Table 2B ; Hilgert et al., 2009) . GJB2 gene is the most frequent single gene defect leading to HL. It encodes Connexin 26, a gap junction subunit that is highly expressed in cochlea (important for potassium recycling into stria vascularis during mechanosensory transduction of sound). These patients develop a non-progressive, severe to profound bilateral SNHL (with a down-sloping or flat audiometry) early in life (mostly prelingual) (Finsterer & Fellinger, 2005; Ouyang et al., 2009) with intact vestibular function (Denoyelle et al., 1999) .
SLC26A4 encodes for Pendrin, a trans-membrane chloride/iodide pump, and maintains the homeostasis of endolymph. Clinical presentation of DFNB4 include prelingual, bilateral, highfrequency SNHL and in 20% of patients an enlarged vestibular aqueduct, which makes it difficult to distinguish from Pendred syndrome (Campbell et al., 2001; Hilgert et al., 2009) . Some of the other major forms of non-syndromic AR HL are described in Table 2B . (Grundfast et al., 2000) . Analysis of Y-linked genes discovered that genes give rise to isolated HL rather than HL associated with syndromes (Petersen, Wang, & Willems, 2007) .
Alport syndrome, the most well-known X-linked syndromic cause of HL, comprises about 1% of individuals with severe to profound HL. The syndrome presents with progressive SNHL, kidney disease, and ocular problems (Govan, 1983; Petersen et al., 2007) .
Mutated mitochondrial DNA (mtDNA) is responsible for up to 2% of HL (Hutchin & Cortopassi, 2000; Petersen, 2002) . Most of identified mutated genes in mtDNA cause isolated, non-syndromic HL. The HL typically develops after onset of other clinical features at a later age and is mostly sensorineural (Jacobs et al., 2004; Kochhar et al., 2007) . Table 3A contains more information on X-linked and mitochondrial causes of syndromic HL. Non-syndromic HL due to single X-linked or mitochondrial gene defects is rare but important because of their distinctive inheritance pattern. In almost 50% of all pedigrees with X-linked non-syndromic HL, mutations in DFN3 locus are found. This locus contains the POU3F4 gene that encodes a transcription factor . This is the same gene accountable for Gusher syndrome. Affected males present with a progressive, moderate to severe mixed HL usually in their first decade of life. Gusher can be distinguished from DFN3 by vestibular problems (Finsterer & Fellinger, 2005; Petersen et al., 2007) .
Mutations of mtDNA cause a broad spectrum of maternally inherited abnormalities. However, some of the mutations in mitochondrial genes manifest as a non-syndromic HL, which is generally a progressive bilateral SNHL (Guan, 2004) . Mutations of MT-RNR1 and MT-TS1 genes have been identified to cause maternally inherited SNHL. Almost all mutations of 12S-sRNA and few mutations of tRNAs increase susceptibility to aminoglycoside-induced SNHL (FischelGhodsian et al., 1997; Kokotas, Petersen, & Willems, 2007; Xing, Chen, & Cao, 2007) .
Diagnostic Methods and Screening
An estimated 24,000 infants are born with HL in the United States each year while only 400 infants are diagnosed with phenylketonuria at birth. Yet, the necessity of screening tests for HHI have not been recognized universally (Grundfast et al., 2000) . Currently, some laboratories offer commercially available screening or diagnostic genetic tests and some provide audioprofiling tests to predict an underlying genetic basis. For instance, the Laboratory for Molecular Medicine of Partners Healthcare Center for Personalized Genetic Medicine (PCPGM) offers physicians access to 33 genetic diagnostic and screening tests for HL (Kothiyal et al., 2010) . The University of Iowa has developed the software, AudioGene, to predict AD non-syndromic HL (Hildebrand et al., 2009) .
Identifying a patient's genetic basis for HL solidifies a diagnosis. It also allows the physician to tailor treatments and therapies towards a particular HL genotype for better patient outcomes. A physician should only offer a patient a genetic test to determine their molecular basis of HL after a thorough history, physical exam, and proper audiology testing have been performed. This allows the physician to decide on further tests (genetic, imaging, etc.) according to the patient's specific presentation and family history (Rehm, 2005; Smith & Hone, 2003) . A recent study examining the steps in diagnosis of HL found different modalities of diagnosis and screening might be more or less informative depending on the patient's ethnicity. For example, it was shown that Asian patients had a higher yield with genetic testing than imaging studies due to the high prevalence of GJB2 mutation in this ethnic group (Chan, Schrijver, & Chang, 2011) .
For patients with syndromic HL, physicians can obtain a genetic panels for known patterns of gene deletions. In addition, patients with HL attributed to certain families or ethnicspecific patterns of HL (e.g., Ashkenazi Jewish or French Canadian) could be tested with specific panels for HL based on common HL genes affecting their ethnicity (Chan et al., 2011) .
A previous algorithm for genetic testing using single gene studies of patients with nonsyndromic bilateral SNHL has been previously published (Matsunaga, 2009) . In this algorithm, the first test involves the gene GJB2 because it is the most common cause of non-syndromic HL and responsible for up to half of AR non-syndromic HL. If only one mutation is found, a test looking for the GJB6 deletion would be the next logical step. Residing directly adjacent to the GJB2 gene, the GJB6 gene is located in a region that is known to be deleted in many patients with a single GJB2 mutation. If these tests are negative, any other tests that are available for AR non-syndromic HL should be chosen at the physician's discretion.
Audioprofiling is a novel tool for detection of defective genes in small families with HL. Based on frequencies and hearing thresholds, audioprofiling enables the categorization of phenotypic data (in our case audiograms) and establishment genotypic correlations (Meyer, Nishimura, McMordie, & Smith, 2007) . AudioGene, a commercially available machine-based audioprofiling system, analyzes audiograms of small families with ADHL to predict the most probable defective genes and loci for mutation screening. However, it is only available for AD patterns of HL (de Heer et al., 2011; Hildebrand et al., 2009) . Although methods to predict mutated genes in AR pattern of HL have been introduced (Meyer et al., 2007) , they are not commercially available yet. A summary of currently available genetic tests to aid in the diagnosis of HL can be found in Table 4 . 
